Journal article
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer
Anti-cancer drugs, Vol.26(6), pp.682-686
07/2015
DOI: 10.1097/CAD.0000000000000233
PMID: 25811963
Abstract
The primary objective of this study was to determine the activity and safety of 3-weekly oxaliplatin combined with gemcitabine and oral capecitabine in the first-line treatment of advanced biliary tract cancer. Treatment consisted of intravenous oxaliplatin 100 mg/m(2) every 3 weeks combined with intravenous gemcitabine 1000 mg/m(2) on days 1 and 8 and oral capecitabine 1500 mg/m(2) 14 days on 21 in two divided doses. Treatment was administered until progressive disease, unacceptable toxicity, or patient refusal. Thirty-seven patients were enrolled: eight patients had Eastern Cooperative Oncology Group 2 performance status at presentation. The overall response rate was 35.1% [95% confidence interval (CI): 20.2-52.5%] and the disease control rate was 72.9%. The median progression-free survival was 9.4 months (95% CI: 4.1-12.2 months) and the median overall survival was 13.8 months (95% CI: 7.7-17.1 months). There were no grade 4 toxicities. Grade 3 neutropenia occurred in 13.5% of patients and grade 3 thrombocytopenia in 10.8%. The present study suggests that 3-weekly oxaliplatin combined with gemcitabine and oral capecitabine is an active and well-tolerated chemotherapy regimen in the first-line treatment of metastatic biliary tract cancer. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.
Details
- Title: Subtitle
- Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer
- Creators
- Roberto Petrioli - University of SienaGiandomenico Roviello - University of SienaAnna I. Fiaschi - University of SienaLetizia Laera - University of SienaFranco Roviello - Center for Special Minimally Invasive and Robotic SurgeryDaniele Marrelli - University of SienaEdoardo Francini - Policlinico Umberto I
- Resource Type
- Journal article
- Publication Details
- Anti-cancer drugs, Vol.26(6), pp.682-686
- DOI
- 10.1097/CAD.0000000000000233
- PMID
- 25811963
- ISSN
- 0959-4973
- eISSN
- 1473-5741
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 5
- Language
- English
- Date published
- 07/2015
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221244002771
Metrics
1 Record Views